用AI多代理系统自动开发CAR-T疗法，提升靶点筛选与安全性评估效率。
Bio AI Agent: A Multi-Agent Artificial Intelligence System for Autonomous CAR-T Cell Therapy Development with Integrated Target Discovery, Toxicity Prediction, and Rational Molecular Design
- 六类专业AI代理协同工作，覆盖靶点发现到临床转化全流程。
- 成功识别出高风险靶点如FcRH5和CD229，并预警专利侵权问题。
- 适合生物医药研发团队、AI制药公司及精准肿瘤治疗研究者使用。
嵌合抗原受体T细胞（CAR-T）疗法代表癌症治疗的范式转变，但其开发周期长达8-12年，临床淘汰率超过40%-60%，暴露出靶点选择、安全评估与分子优化中的关键低效。我们提出Bio AI Agent，一个基于大语言模型的多代理人工智能系统，实现CAR-T疗法的自主开发。系统包含六个自治代理：靶点筛选代理对超过10,000个癌症相关靶点进行多参数优先排序；毒性预测代理整合组织表达图谱与药物警戒数据库进行全方位安全评估；分子设计代理实现理性化CAR工程；专利情报代理开展自由实施分析；临床转化代理确保合规性；决策编排代理负责多代理协调。回顾性验证显示，系统自主识别出高风险靶点如FcRH5（肝毒性）和CD229（脱瘤毒性），发现CD38+SLAMF7组合的专利侵权风险，并生成完整开发路线图。通过并行处理、专业化推理与自主决策，该系统在精准肿瘤学开发中弥补了关键空白，有望加速下一代免疫疗法从发现到临床的转化。
原文摘要 · Abstract (English)
Chimeric antigen receptor T-cell (CAR-T) therapy represents a paradigm shift in cancer treatment, yet development timelines of 8-12 years and clinical attrition rates exceeding 40-60% highlight critical inefficiencies in target selection, safety assessment, and molecular optimization. We present Bio AI Agent, a multi-agent artificial intelligence system powered by large language models that enables autonomous CAR-T development through collaborative specialized agents. The system comprises six autonomous agents: Target Selection Agent for multi-parametric antigen prioritization across >10,000 cancer-associated targets, Toxicity Prediction Agent for comprehensive safety profiling integrating tissue expression atlases and pharmacovigilance databases, Molecular Design Agent for rational CAR engineering, Patent Intelligence Agent for freedom-to-operate analysis, Clinical Translation Agent for regulatory compliance, and Decision Orchestration Agent for multi-agent coordination. Retrospective validation demonstrated autonomous identification of high-risk targets including FcRH5 (hepatotoxicity) and CD229 (off-tumor toxicity), patent infringement risks for CD38+SLAMF7 combinations, and generation of comprehensive development roadmaps. By enabling parallel processing, specialized reasoning, and autonomous decision-making superior to monolithic AI systems, Bio AI Agent addresses critical gaps in precision oncology development and has potential to accelerate translation of next-generation immunotherapies from discovery to clinic.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品；中文卡片由大模型生成，请以原文为准。